United Kingdom Cancer Diagnostics Market to be dominated by Breast Cancer till 2027
The growing popularity of
personalized treatment and the rise in the old age population is expected to
drive the demand for the United Kingdom cancer diagnostics market throughout
the forecast period.
According to TechSci Research report, “United
Kingdom Cancer Diagnostics Market By Region, Competition Forecast &
Opportunities, 2027”, the United Kingdom cancer diagnostics market is
expected to witness robust growth in the forecast period. Cancer diagnostics is
a process of identifying different proteins, biomarkers, or any other signs
that can reveal the presence of a cancerous tumor in the body. Diagnostic
testing is a crucial process that can validate or eliminate the existence of an
illness and monitor the stage of the disease. It helps the healthcare
professionals to decide the course of action and predict and review the
treatment outcomes. The diagnostic procedures which help the patients to identify
cancer are laboratory tests, surgery, genetic testing, tumor biopsy, imaging,
tumor biopsy, or endoscopic testing. Factors such as the rise in consumer
awareness about the benefits of early diagnosis and treatment and the increase
in the number of diagnostic laboratories are primarily driving the growth of
the United Kingdom cancer diagnostics market in the forecast period. Increased
adoption of unhealthy eating habits and a sedentary lifestyle has escalated the
occurrence of cancer across the country.
However, the high cost of the diagnostic imaging
system and the development of different treatment approaches for cancer
mutations may restrain the growth of the United Kingdom cancer diagnostics
market in the forecast period.
Browse XX Figures spread through XX Pages and an
in-depth TOC on "United Kingdom Cancer Diagnostics Market”.
https://www.techsciresearch.com/report/united-kingdom-cancer-diagnostics-market/10573.html
United
Kingdom cancer diagnostics market is segmented into product, technology, application, end user, regional distribution, and
competitive landscape.
Based on product, the market
is bifurcated into consumables and instruments. Consumables are dominating the
market and are expected to maintain their dominance over the next five years
owing to the rise in the adoption of consumables for cancer diagnostics and high-end
investments for research and development activities. The launch of
technologically advanced kits & reagents in the market and the growing old
age population are the other prominent drivers expected to drive the segment
demand.
Based on technology, the
market is divided into IVD testing, imaging, and biopsy. Imaging technology is
expected to account for a significant market share in the forecast period. By
using imaging technology, healthcare professionals can easily decide the course
of action. The constant rise in the number of cancer patients is accelerating
the demand for imaging modalities in the country.
Based on application, the
market is divided into breast cancer, lung cancer, colorectal cancer, and
others. The breast cancer segment is expected to capture the highest market
share in the forecast period as it is the most common type of cancer in the
United Kingdom. The majority of the women diagnosed with cancer are above age
50. According to National Health Service, about 1 in 8 women are diagnosed with
cancer in their lifetime, making it necessary for women to check their breasts
at regular intervals. Early detection of cancer in patients can be led to
better treatment and recovery of patients.
Based on the end user, the
market is divided into hospitals & clinics, diagnostic laboratories, and
others. Hospitals & clinics are expected to hold the largest market share
in the next five years. The high footfall of patients and rise in the number of
in-house diagnostic procedures performed in hospitals are driving the segment
demand.
Major
market players operating in the United Kingdom cancer diagnostics market are:
·
GE Healthcare UK Limited
·
Becton, Dickinson U.K. Limited
·
Roche Diagnostics UK
·
Abbott Laboratories Limited
·
Fujifilm Healthcare UK Limited
·
Hologic (UK) Limited
·
Agilent Technologies UK Limited
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=10573
Customers can also
request for 10% free customization on this report.
“Market
players allocate huge funds for research and development activities to upgrade
existing infrastructure and find novel cancer diagnostic technologies. Patients
have started to prefer non-invasive diagnostic procedures, which creates
numerous possibilities for the market players to develop new innovative solutions.
Also, the rise in the development of CT scanners with enhanced resolution and
lower radiation dosage and the development of biopsy technologies and the use
of artificial intelligence technology for early cancer detection are expected
to propel the growth of the United Kingdom cancer diagnostics market till 2027”
said Mr. Karan Chechi, Research Director with TechSci Research, a global research-based
management consulting firm.
“United Kingdom Cancer
Diagnostics Market By Product (Consumables v/s Instruments), By Technology (IVD
Testing, Imaging, Biopsy), By Application (Breast Cancer, Lung Cancer,
Colorectal Cancer, Others), By End User (Hospitals & Clinics, Diagnostic
Laboratories, Others), By Region, Competition Forecast & Opportunities,
2027” has evaluated the future growth potential of United
Kingdom cancer diagnostics market and provided statistics & information on
market size, shares, structure, and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in the
of United Kingdom cancer diagnostics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Web:
https://www.techsciresearch.com